
Hoth Therapeutics (HOTH) Stock Forecast & Price Target
Hoth Therapeutics (HOTH) Analyst Ratings
Bulls say
Hoth Therapeutics is a potential buy for investors due to its strategically diversified pipeline and positive clinical data, including support for continued development and dose optimization for the topical cancer treatment, HT-001. Upcoming catalysts, such as phase II trial approvals and potential data readouts from the CLEER-001 study, could drive further growth for the company. However, investors should also consider potential risks, including clinical/regulatory, financial, commercial, and legal risks that could impact the company's progress.
Bears say
Hoth Therapeutics is a high-risk investment due to the early stage of its drug development programs, lack of controlled efficacy data, and reliance on partnerships for funding. Additionally, potential competitors and the complexity of obtaining regulatory approval for new drugs pose further risks to the company's success.
This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Hoth Therapeutics (HOTH) Analyst Forecast & Price Prediction
Start investing in Hoth Therapeutics (HOTH)
Order type
Buy in
Order amount
Est. shares
0 shares